Theseus Pharmaceuticals Inc

Theseus Pharmaceuticals — Investor Presentation (May 2023)

46 slides from Theseus Pharmaceuticals's investor presentation, May 25, 2023

  1. Slide 1: Theseus Pharmaceuticals: A new generation of medicines to address cancer resistance

    Theseus Pharmaceuticals A new generation of medicines to address cancer resistance May 2023 | THRX

  2. Slide 2: Legal notice and forward-looking statements

    Legal notice and forward-looking statements ©2023 Theseus Pharmaceuticals. Certain statements included in this presentation are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995.

  3. Slide 3: Developing next-generation pan-variant TKI candidates for treatment-resistant cancer

    ©2023 Theseus Pharmaceuticals. Theseus is developing next-generation, single molecule pan-variant TKI candidates for treatment- resistant cancer Led by world-class R&D team with deep experience developing and commercializing novel targeted therapies in validated areas of unmet medical need Different

  4. Slide 4: Executing on a novel pipeline of targeted therapies

    Second program: THE-349 (EGFR-mutant NSCLC) Lead program: THE-630 (GIST) • KIT-driven GIST is a clonally heterogeneous disease which requires a pan-variant inhibitor to meaningfully improve patient outcomes • Enrolling patients in phase 1 portion of phase 1/2 study; preliminary dose escalation data

  5. Slide 5: Experienced management team leveraging heritage of success

    Bill Shakespeare, Ph.D. Co-founder, President of R&D Former VP Drug Discovery, ARIAD Experienced management team leveraging heritage of success Vic Rivera, Ph.D. Co-founder, CSO Former VP Preclinical & Translational Research, ARIAD David Kerstein, M.D. CMO Former CMO, Anchiano Former Sr. Med Dir, AR

  6. Slide 6: Extensive experience and track record in TKI discovery, development, and commercialization

    Extensive experience and track record in TKI discovery, development, and commercialization ©2023 Theseus Pharmaceuticals. Validated methodology & approach at ARIAD that produced three approved TKIs World-class team Leveraging prior achievements in the discovery, development and commercialization of

  7. Slide 7: The problem

    The problem ©2023 Theseus Pharmaceuticals. Tumor On-target resistance mutations emerge in response to targeted therapies, limiting the efficacy of such therapies Clonal heterogeneity develops over time, leading to disease complexity and tumor progression TKI = tyrosine kinase inhibitor. 7

  8. Slide 8: Our solution

    Our solution ©2023 Theseus Pharmaceuticals. Tumor Theseus’ next-generation, pan- variant TKIs are designed to simultaneously inhibit all major cancer-causing and resistance mutations, which has the potential to yield prolonged clinical benefit in early and late lines of treatment TKI = tyrosine kina

  9. Slide 9: Theseus' approach: TKI candidates developed iteratively to optimize pan-variant activity

    Theseus’ approach: TKI candidates are developed iteratively to optimize pan-variant activity ©2023 Theseus Pharmaceuticals. Structure-Guided Design In silico: Uses 3D structures of the target TK to design a TKI with multiple molecular touch points to maintain binding in the presence of any variants

  10. Slide 10: Growing pipeline of targeted cancer therapies

    Growing pipeline of targeted cancer therapies ©2023 Theseus Pharmaceuticals.Note: We hold a worldwide exclusive license to THE-630 in our therapeutic area of focus through the ARIAD License Agreement, as defined and described in our filings with the Securities and Exchange Commission. CML = Chronic

  11. Slide 11: THE-630: Pan-variant KIT Inhibitor Candidate

    THE-630: Pan-variant KIT Inhibitor Candidate

  12. Slide 12: GIST is one of targeted oncology's great unmet patient needs

    GIST is one of targeted oncology’s great unmet patient needs Sources: Corless, C. Modern Pathol 2014;27,s1-s16. GIST = Gastrointestinal Stromal Tumors. GIST is the most common sarcoma of the GI tract with ~4,000-6,000 new cases in the U.S. each year • ~80% of GIST patients present with an activating

  13. Slide 13: 2L+ GIST progresses rapidly; current therapies are inadequate

    2L+ GIST progresses rapidly; current therapies are inadequate Sources: Clarivate, DRG, Gleevec ® (imatinib) USPI, Sutent ® (sunitinib) USPI, Stivarga ® (regorafenib) USPI, Qinlock ® (ripretinib USPI). Stivarga ® ORR from Demetri, Lancet, 2013. 2L = Second Line. GIST = Gastrointestinal Stromal Tumors

  14. Slide 14: Predictive Resistance Assay rationalizes deficiencies of approved KIT inhibitors

    Our novel Predictive Resistance Assay™ rationalizes known deficiencies of approved KIT inhibitors for GIST Cav = average serum concentration, and is calculated as the Area Under the Curve, or AUC, over a 24-hour period and divided by 24. GIST = Gastrointestinal Stromal Tumors. Ex = exon. nM = nanomo

  15. Slide 15: Pan-variant inhibitor is critical for effective treatment in 2L GIST

    Clinical data suggest a pan-variant inhibitor is critical for effective treatment in patients with 2L GIST • 2L GIST is heterogeneous and remains a significant unmet need • INTRIGUE study demonstrated no difference in PFS between ripretinib and sunitinib because neither has coverage of both sets of

  16. Slide 16: THE-630 could be the only therapy covering all major mutation classes

    THE-630 could be the only therapy with coverage of all major classes of activating and resistance mutations ©2023 Theseus Pharmaceuticals.Based on data from our PRA (Predictive Resistance Assay™). PD = progressive disease. PR/CR = partial/complete response. SD = stable disease. (1) Assumes target Ca

  17. Slide 17: Phase 1/2 trial design

    Phase 1/2 trial design Phase 1 – Dose Escalation THE-630 once daily (QD) 3 + 3 dose escalation design Backfill enrollment (up to 40 patients) ≥5th Line cohort prior imatinib, sunitinib, regorafenib, and ripretinib (N=~20) 3rd-4th Line cohort prior imatinib and sunitinib, 0-1 additional lines of ther

  18. Slide 18: Registration strategy for THE-630: rapidly advance to 2L

    Registration strategy for THE-630: rapidly advance to 2L Targeting rapid advancement to 2L development, with plans to commence a 2L registrational study shortly after beginning our 5L registrational study Ongoing dose escalation Planned Phase 2 dose expansion Planned registrational studies Ongoing p

  19. Slide 19: Standard 3+3 dose escalation design

    Standard 3+3 dose escalation design • DLT evaluation period = 28 days • Dose level increases of up to 100% until one of the following: – Grade ≥ 2 non-hematologic or ≥ grade 3 hematological AE for which relationship to THE-630 cannot be ruled out – DLT – 48 mg dose level • Then, dose level increases

  20. Slide 20: Baseline characteristics: heavily pretreated KIT-mutant GIST population

    Baseline characteristics: heavily pretreated KIT-mutant GIST population 20 Demographics and Baseline Characteristics Total N=23 Median age, years 59 Female, n (%) 10 (43.5) ECOG Performance Status, n (%) 0 11 (47.8) 1 11 (47.8) 2 1 (4.3) Stage at Screening Stage IV, n (%) 23 (100) Number of unique p

  21. Slide 21: Dose escalation (Cohorts 1-6)

    Dose escalation (Cohorts 1-6) 21 AE = adverse event. C1D1 = Cycle 1 Day 1. Cav = average serum concentration. DLT = dose-limiting toxicity. ECOG Performance Status = Eastern Cooperative Oncology Group Performance Status. GIST = Gastrointestinal Stromal Tumors. PE = Pulmonary Embolism. QD = once dail

  22. Slide 22: Safety profile supports continued dose escalation

    Safety profile supports continued dose escalation • 65% of patients had treatment-related adverse events (AE) of any grade − Most common (≥10%) treatment- related AEs include fatigue, AST increased, diarrhea, nausea, dry mouth, and dyspnea − Treatment-related AEs were predominantly grade 1-2: of 89

  23. Slide 23: Pharmacokinetics consistent with once-daily oral dosing

    Pharmacokinetics consistent with once-daily oral dosing 23 • 3-6-fold accumulation observed from C1D1 to C1D15 • Approximately linear increase in systemic exposure at steady state through Cohort 6 - Cohort 5 (12 mg): mean Cav 46.6 nM with high inter-patient variability - Cohort 6 (18 mg): mean Cav 4

  24. Slide 24: Prolonged stable disease observed at higher doses

    Prolonged stable disease observed at higher doses       0 4 8 12 16 20 24 28 32 36 1 (4) 2 (5) 3 (5) 4 (4) 5 (4) 6 (4) 7 (3) 8 (3) 9 (8) 10 (4) 11 (4) 12 (6) 13 (4) 14 (4) 15 (2) 16 (3) 17 (2) 18 (2) 19 (4) 20 (4) 21 (4) 22 (4) 23 (3) Time on treatment (weeks) a Escalated to 6 mg in week 24 an

  25. Slide 25: Reductions observed in KIT mutant allele fractions in ctDNA

    8 315 76 11 122 5 4 16 14 712 11 51 2 14 16 12 4 15 16 165 1920 22 2219 19 19 1922191912 A 50 2_ Y5 03 du p A 50 2_ Y5 03 du p A 50 2_ Y5 03 du p A 50 2_ Y5 03 du p E5 54 _V 55 5d el W 55 7_ K5 58 de l M 55 2_ Y5 70 de l W 55 7_ V5 60 de lin sC W 55 7_ E5 62 de lin sV M 55 2_ E5 61 de lin sQ K 55 8_

  26. Slide 26: Concomitant ctDNA reduction and stable disease at higher doses

    17 11, 17 9 11, 17 11, 16, 17 11 11,13 9 11 (No post-BL) 11^, 134x, 142x, 1710x,18 (No post-BL) 11, 13 11, 132x,17 None detected in ctDNA 11, 17 9, 17 11, 173x 11##, 13## None detected in ctDNA 11^^, 133x, 172x, 19 9 To be analyzed 11†, 13, 14 To be analyzed Con

  27. Slide 27: Clinical ctDNA observations consistent with PRA predictions

    Clinical ctDNA observations consistent with PRA predictions Clinical ctDNA observed in trial Target (~40 mg) Cohort 5/6 (12/18 mg) Cohort 4 (9 mg) Cohort 3 (6 mg) Cohort 2 (4 mg) Cohort 1 (3 mg) ctDNA effects shown are the best fold change in mutant allele frequency (MAF). ctDNA = circulating tumor

  28. Slide 28: THE-630 building the foundation for a best-in-class KIT inhibitor for GIST

    THE-630 – building the foundation for a best-in-class KIT inhibitor for patients with GIST 28 Next data update expected Q4 2023 Part 2: Dose expansion (2L, 3L/4L, 5L) 2L = Second Line. 3L = Third Line. 4L = Fourth Line. 5L = Fifth Line. ctDNA = circulating tumor DNA. mPFS = median progression free s

  29. Slide 29: THE-349: Fourth-Generation EGFR Inhibitor Candidate

    THE-349: Fourth-Generation EGFR Inhibitor Candidate

  30. Slide 30: EGFRm NSCLC overview

    EGFRm NSCLC overview 30 ©2023 Theseus Pharmaceuticals. There is no approved TKI to address all combinations of major EGFR activating and resistance mutations • EGFR mutations are a key driver of NSCLC, with approximately 18,000 first-line EGFRm NSCLC patients in the United States with mutations in e

  31. Slide 31: Treatment paradigm for EGFRm NSCLC

    Treatment paradigm for EGFRm NSCLC 31 ©2023 Theseus Pharmaceuticals. Exon 19 deletion (D) or L858R (L) activating mutation EGFR mutation T790M resistance mutation (T) + D or L = DT or LT C797S resistance mutation (C) + D or L = DC or LC C797S resistance mutation (C) + DT or LT = DTC or LTC • Selecti

  32. Slide 32: THE-349 potently inhibits single-, double-, and triple-mutants

    Preclinical data has demonstrated THE-349 potently inhibits single-, double-, and triple-mutants, including T790M and C797S 32 ©2023 Theseus Pharmaceuticals. Mutational Coverage L858R or Exon 19 del L858R or Exon 19 del + T790M L858R or Exon 19 del + C797S L858R or Exon 19 del + T790M + C797S THE-34

  33. Slide 33: THE-349 potent and selective EGFR mutant activity with kinome selectivity

    THE-349 exhibits potent and selective EGFR mutant activity with significant kinome selectivity in vitro 33 ©2023 Theseus Pharmaceuticals. THE-349 demonstrates low nanomolar IC50 values against single-, double- and triple-mutant EGFR variants with wild-type selectivity which exceeds that of erlotinib

  34. Slide 34: THE-349 robust tumor regression in mouse models

    THE-349 has robust tumor regression activity in mouse models expressing EGFR single-, double- and triple-mutant variants at well- tolerated doses 34 ©2023 Theseus Pharmaceuticals.Note: Data from the 2022 EORTC-NCI-AACR (ENA) Symposium. Poster #236. EGFR = Epidermal Growth Factor Receptor. TGI = tumo

  35. Slide 35: THE-349 deep, durable regressions in osimertinib-resistant PDX model

    THE-349 induced deep, durable regressions in clonally heterogeneous osimertinib-resistant PDX model Model developed from patient with NSCLC after failure of >5 lines of therapy (including erlotinib and osimertinib) • Model reflects clonal heterogeneity – mixture of DTC and original D primary mutatio

  36. Slide 36: THE-349 is active in CNS with favorable drug-like properties

    THE-349 is active in CNS and has displayed favorable drug-like properties in mouse models 36 ©2023 Theseus Pharmaceuticals.Note: Data from the 2022 EORTC-NCI-AACR (ENA) Symposium. Poster #236. CNS = central nervous system. EGFR = Epidermal Growth Factor Receptor. NSCLC = Non-Small Cell Lung Cancer.

  37. Slide 37: Clinical development plan for THE-349

    Clinical development plan for THE-349 37 ©2023 Theseus Pharmaceuticals. Theseus plans to pursue an initial registration as monotherapy in patients with on-target resistance, as well as rapidly expand into evaluation of combinations and, if clinical data support, target the broader 2L market, which c

  38. Slide 38: BCR-ABL Program

    @) THESEUS BCR-ABL Program

  39. Slide 39: Approved BCR-ABL inhibitors have limitations in balancing efficacy and safety

    Approved BCR-ABL inhibitors have limitations because they do not optimally balance efficacy and safety 39 ©2023 Theseus Pharmaceuticals. Generation Safety/tolerability(1) Efficacy/pan-ness(2) CML Indication Adult Ph+ ALL Indication Target Product Profile for Theseus BCR-ABL Inhibitor 5G ≥2L (target)

  40. Slide 40: Key features of CML

    Key features of CML 40 ©2023 Theseus Pharmaceuticals. • Disease remains BCR-ABL driven through multiple lines of therapy, and patients commonly will relapse with a BCR-ABL resistance mutation • Multiple therapies have been approved; however, approximately 30% to 40% of patients started on any TKI wi

  41. Slide 41: Key features of adult Ph+ ALL

    Key features of adult Ph+ ALL 41 ©2023 Theseus Pharmaceuticals. • Newly diagnosed adults have historically received chemotherapy followed by allogeneic hematopoietic stem-cell transplant (HSCT), and more recently the addition of BCR-ABL TKIs have improved outcomes in 1L treatment, despite their lack

  42. Slide 42: Target product profile for Theseus' pan-variant BCR-ABL TKI

    Target product profile for Theseus’ pan-variant BCR-ABL TKI 42 ©2023 Theseus Pharmaceuticals. Compound Company Generation 2021 FY Sales (USD) Imatinib (Gleevec®) Novartis 1G $1.0bn Dasatinib (Sprycel®) Bristol Myers Squibb 2G $2.1bn Nilotinib (Tasigna®) Novartis 2G $2.0bn Bosutinib (Bosulif®) Pfizer

  43. Slide 43: In vitro pan-BCR-ABL activity with increased selectivity versus ponatinib

    In vitro characterization demonstrated pan-BCR-ABL activity with increased selectivity versus ponatinib 43 ©2023 Theseus Pharmaceuticals. On-target BCR-ABL potency (BaF3 IC50 nM) Off-target potency (BaF3 IC50 nM) Endothelial cell tox (IC25 nM) Kinome selectivity Cmpd WT T315I E255V F359V KDR FLT3 FG

  44. Slide 44: Similar tumor regression and superior tolerability to ponatinib in vivo

    Theseus molecule showed similar tumor regression activity and superior tolerability to ponatinib in vivo 44 ©2023 Theseus Pharmaceuticals. Activity against most recalcitrant mutant (E255V) Compound 1 induced strong tumor regressions against the most recalcitrant mutant and demonstrated improved tole

  45. Slide 45: Executing on a novel pipeline of targeted therapies

    Second program: THE-349 (EGFR-mutant NSCLC) Lead program: THE-630 (GIST) • KIT-driven GIST is a clonally heterogeneous disease which requires a pan-variant inhibitor to meaningfully improve patient outcomes • Enrolling patients in phase 1 portion of phase 1/2 study; preliminary dose escalation data

  46. Slide 46: © THESEUS

    © THESEUS

Theseus Pharmaceuticals — Investor Presentation (May 2023) on 6ix